

REVENIO

Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2018-2020

Revenio Group Corporation, Stock Exchange Release, 15.2.2021 at 15:00

Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2018-2020

The Board of Directors of Revenio Group Corporation decided, on 15 February 2021, on the basis of the share issue authorisation granted to the Board of Directors by the company's Annual General Meeting held on 8 June 2020, to issue shares in a directed share issue without payment to pay the shares earned by the company's key persons during the performance period 2018-2020 of the share-based incentive scheme.

The shares to be issued in the directed share issue without payment are issued in accordance with the terms and conditions of the company's current share-based incentive scheme to enhance the stability and work motivation of personnel, and thus there is an especially weighty financial reason for the share issue and for the derogation of the pre-emptive right of shareholders as provided in Chapter 9, Section 4(1) of the Finnish Limited Liability Companies Act. The establishment and main terms and conditions of the share-based incentive scheme were announced in a stock exchange release published on 20 April 2018 and on the company's website.

A total of 12 253 of the company's treasury shares will be transferred in a directed issue free of charge to persons included in the share-based incentive scheme. After the transfers, the company holds 118 805 treasury shares.

Revenio Group Corporation
Board of Directors

For further information, please contact:

CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi

CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Ltd
Financial Supervisory Authority
Main media
www.revenio.fi

REVENIO

Revenio Group in brief

Revenio is an internationally operating health technology corporation and a globally leading supplier of ophthalmic devices. Revenio Group's eye diagnostics solutions include tonometers, retinal imaging apparatus and perimeters under the iCare brand. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group consists of Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

In 2020, Revenio Group's net sales totalled EUR 61.1 million, with its net operating profit standing at 17.1%. Revenio Group Corporation's shares are listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2018-2020](#)